You paid. The history sat in a form, if it showed up at all. Nobody called.
People write that they could not reach a human after they already paid for a GLP-1. Public one-star pages keep the same complaint. Chat. A missed visit. A phone that does not get answered. They needed someone who had read the file. They are trying to sort GLP-1 thyroid gallbladder risk without a person on the line.
I have been counting those pages by hand. Angry people post. People who got a careful visit stay quiet. The sample is not a census. The hole is still easy to see.
What the FDA label wants you to say
FDA-approved weekly GLP-1 shots used for weight carry a boxed warning for a rare thyroid cancer called medullary thyroid carcinoma. DailyMed prescribing information says do not take the medicine if you have that cancer, if a close family member had it, or if you have Multiple Endocrine Neoplasia syndrome type 2. Those are history questions. A TSH test, the usual thyroid hormone check, does not answer them.
In rodents, that weekly shot caused thyroid C-cell tumors. It is unknown whether it causes that cancer in people. The FDA label still wants you told about a lump in the neck. Also trouble swallowing, trouble breathing, or a hoarse voice that does not go away. Routine calcitonin blood tests and thyroid ultrasound are of uncertain value for catching that cancer early, the label says.
An underactive thyroid is a different file. Hashimoto’s is a different file. Say those too. A clinician may still want to know. They are not the boxed stop.
GLP-1 thyroid gallbladder risk is a history question
Acute pancreatitis has shown up with this class. That can mean severe or lasting belly pain, sometimes going into the back, with or without vomiting. If it is suspected, the DailyMed label says stop the medicine and get care. In adult weight-reduction trials, confirmed pancreatitis was uncommon. Four people on the weekly shot. One on placebo.
Tell a clinician if you ever had pancreatitis. Do not let a form skip a hospital stay. Do not let a forum decide what that stay means for you.
Gallbladder trouble showed up more often on the medicine than on placebo. In those adult trials, gallstones were reported by 1.6 percent of people on the weekly shot and 0.7 percent on placebo. Gallbladder inflammation was reported by 0.6 percent against 0.2 percent. Fast weight change can raise the chance of gallstones. The label still found more gallbladder disease on the shot after accounting for how much weight people lost.
If gallstones are suspected, the label wants studies and follow-up. A past gallbladder attack, or a gallbladder that was already removed, still belongs in the visit. A clinician decides what that history means. You do not.
Say the history out loud, even if the form skipped it.
FDA already named a consumer warning for this market. Watch for a company that skips a screening and a prescription from a licensed doctor before sending medicine. Watch for a company that has no licensed doctor available to answer questions after the medicine arrives.
A silent form does not hold that talk.
Ask who reads the history before a pen ships. Ask whether they heard you on a gallbladder problem, a pancreatitis stay, and the rare thyroid cancer question in your family. Then wait for a person, not a chat window.
If the honest answer is that nobody reviews those files, you already know what kind of program you bought.
Compounded GLP-1 copies are not FDA-approved. FDA does not review them for safety, effectiveness, or quality before they are marketed. That is more reason to keep a person in the loop, not less.
A licensed clinician should read your history and your other medicines. They should decide whether this drug is even a fit. If a Living+ clinician declines, you get a full refund.
Talk to your provider. Tell them the gallbladder story, the pancreas story, and the thyroid cancer question before anyone starts.
Sources
- DailyMed: weekly GLP-1 prescribing information, boxed warning, pancreatitis and gallbladder sections
- FDA: weekly GLP-1 injection prescribing information PDF
- American Thyroid Association: Medullary thyroid cancer (TSH usually normal even when MTC is present)
- MedlinePlus: TSH (thyroid-stimulating hormone) test
See what a Living+ plan costs and whether it fits.
